Due to the pervasive role of MCT1 in most cancers, MCT1 inhibition serves as a highly attractive therapeutic target with significant pre-clinical activity observed with AZD3965, MCT1 specific inhibitor, both in vitro and in vivo [6, 24]. Here, SLC16A1 is linked to cancer.